{"id":"vitamin-k-antagonist-warfarin","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":"0.01-0.1","effect":"Warfarin-induced skin necrosis"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-2","effect":"Alopecia"},{"rate":"1-2","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1201519","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin acts as a vitamin K antagonist by inhibiting the enzyme vitamin K epoxide reductase, which is essential for the gamma-carboxylation of vitamin K-dependent coagulation factors. This prevents the synthesis of functional clotting factors II, VII, IX, and X in the liver, leading to prolonged prothrombin time (PT/INR) and reduced thrombotic risk. The anticoagulant effect develops over several days as existing clotting factors are cleared from circulation.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:32.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Acute myocardial infarction with high thromboembolic risk"}]},"trialDetails":[{"nctId":"NCT07471139","phase":"PHASE3","title":"SWITCH: Apixaban vs Vitamin K in HM3","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-06","conditions":"LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding","enrollment":460},{"nctId":"NCT06655376","phase":"PHASE4","title":"Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-10-02","conditions":"Bleeding, Clot Blood","enrollment":128},{"nctId":"NCT07431762","phase":"PHASE4","title":"Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-02-01","conditions":"Valve Replacement Surgery","enrollment":1058},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT07330869","phase":"","title":"Warfarin Effects on Male Fertility After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Città di Lecce Hospital, GVM Care & Research","startDate":"2026-02","conditions":"Male Infertility, Heart Valve Disease","enrollment":90},{"nctId":"NCT03636295","phase":"PHASE3","title":"Low INR to Minimize Bleeding With Mechanical Valves Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-09-05","conditions":"Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement","enrollment":2625},{"nctId":"NCT04258488","phase":"PHASE4","title":"Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement","status":"RECRUITING","sponsor":"Joon Bum Kim","startDate":"2022-02-21","conditions":"AORTIC VALVE DISEASES, Thromboembolism","enrollment":1300},{"nctId":"NCT06138184","phase":"NA","title":"Learning Theory Patient Education for Anticoagulants","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2026-04","conditions":"Knowledge, Attitudes, Practice","enrollment":68},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT02318342","phase":"NA","title":"Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2014-12","conditions":"Prosthetic Valve Thrombosis","enrollment":3000},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","startDate":"2025-02-14","conditions":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","enrollment":3574},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT01130025","phase":"PHASE3","title":"Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-08","conditions":"Venous Thromboembolism","enrollment":900},{"nctId":"NCT06402851","phase":"PHASE4","title":"Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)","status":"RECRUITING","sponsor":"Hospital Sirio-Libanes","startDate":"2024-12-18","conditions":"Atrium; Fibrillation, Chronic Kidney Diseases","enrollment":1500},{"nctId":"NCT04062097","phase":"","title":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2019-09-19","conditions":"Intracranial Hemorrhage","enrollment":104},{"nctId":"NCT06606275","phase":"","title":"The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis","status":"COMPLETED","sponsor":"Abu Dhabi Health Services Company","startDate":"2024-01-01","conditions":"End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)","enrollment":67},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT04437303","phase":"PHASE4","title":"Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2020-11-25","conditions":"Aortic Valve Disease, Aortic Valve Stenosis, Stroke","enrollment":858},{"nctId":"NCT02046460","phase":"PHASE3","title":"Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD","status":"COMPLETED","sponsor":"Stefan Engelter","startDate":"2013-09","conditions":"Cervical Artery Dissection","enrollment":194},{"nctId":"NCT01556659","phase":"NA","title":"LV Thrombus After Acute AMI: A Randomized Controlled Trial","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2012-03","conditions":"Ventricular Thrombosis Mural Following Myocardial Infarction","enrollment":25},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT05022758","phase":"","title":"A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-10-06","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":45000},{"nctId":"NCT05375474","phase":"PHASE4","title":"Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-07-27","conditions":"Transcatheter Aortic Valve Replacement, Antithrombotic Therapy, Bioprosthetic Valve Thrombosis","enrollment":650},{"nctId":"NCT04730037","phase":"PHASE3","title":"Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2021-03-23","conditions":"CTEPH","enrollment":74},{"nctId":"NCT03757481","phase":"NA","title":"Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PE","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2018-01-01","conditions":"Post Thrombotic Syndrome, Deep Vein Thrombosis, Chronic Thromboembolic Pulmonary Hypertension","enrollment":156},{"nctId":"NCT05022563","phase":"","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Venous Thromboembolism","enrollment":55759},{"nctId":"NCT02740712","phase":"PHASE1","title":"Pharmacokinetic Drug-Drug Interaction Study of Rucaparib","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-04","conditions":"Neoplasms","enrollment":17},{"nctId":"NCT03764241","phase":"PHASE3","title":"Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":280},{"nctId":"NCT03977363","phase":"","title":"The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)","status":"TERMINATED","sponsor":"CHAD","startDate":"2020-01-27","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":25},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT02219984","phase":"","title":"START-Register: Survey on Anticoagulated Patients Register","status":"RECRUITING","sponsor":"GUALTIERO PALARETI","startDate":"2011-10","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":15410},{"nctId":"NCT03178864","phase":"PHASE2","title":"Study of Rivaroxaban for CeREbral Venous Thrombosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-03-12","conditions":"Cerebral Venous Thrombosis","enrollment":55},{"nctId":"NCT02832544","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-08-22","conditions":"Rheumatic Heart Disease","enrollment":4565},{"nctId":"NCT02981472","phase":"PHASE2","title":"A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-19","conditions":"Thrombosis","enrollment":192},{"nctId":"NCT04073316","phase":"PHASE4","title":"AntiCoagulants and COGnition","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2020-02-13","conditions":"Nonvalvular Atrial Fibrillation","enrollment":48},{"nctId":"NCT03153150","phase":"PHASE3","title":"Start or STop Anticoagulants Randomised Trial (SoSTART)","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-03-28","conditions":"Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage","enrollment":203},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Atrial Fibrillation","enrollment":159},{"nctId":"NCT03847181","phase":"","title":"Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-02-28","conditions":"Atrial Fibrillation","enrollment":45164},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT03232398","phase":"PHASE3","title":"Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2018-01-01","conditions":"Acute Myocardial Infarction, Left Ventricular Thrombosis, Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT02319460","phase":"","title":"An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-04-24","conditions":"Hemorrhage","enrollment":2238},{"nctId":"NCT04099238","phase":"","title":"Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-01","conditions":"Atrial Fibrillation","enrollment":3739},{"nctId":"NCT03799822","phase":"PHASE4","title":"Oral Anticoagulation in Hemodialysis","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2017-05-01","conditions":"Atrial Fibrillation","enrollment":132},{"nctId":"NCT02066662","phase":"PHASE4","title":"Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2013-07","conditions":"Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT), Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location","enrollment":192},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT03374540","phase":"","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-01","conditions":"Nonvalvular Atrial Fibrillation","enrollment":78517},{"nctId":"NCT04505475","phase":"","title":"Oral Surgery in Patients Taking Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Novi Sad","startDate":"2015-05-25","conditions":"Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage","enrollment":82},{"nctId":"NCT03566303","phase":"PHASE2, PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis","status":"TERMINATED","sponsor":"Hospital Geral Roberto Santos","startDate":"2018-07-10","conditions":"Prostheses and Implants, Stroke, Valve Heart Disease","enrollment":50},{"nctId":"NCT03359876","phase":"","title":"Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-01","conditions":"Atrial Fibrillation","enrollment":16000},{"nctId":"NCT02161965","phase":"PHASE4","title":"Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2013-05-21","conditions":"Permanent Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism","enrollment":51},{"nctId":"NCT02942576","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-03-21","conditions":"Atrial Fibrillation","enrollment":632},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT03996629","phase":"NA","title":"Impact of Clinical Pharmacist Interventions in Vitamin K Antagonists Management at One Teaching Hospital in Vietnam","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2019-08-01","conditions":"Anticoagulation","enrollment":800},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT02610933","phase":"PHASE4","title":"Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2015-11","conditions":"Vascular Calcification","enrollment":117},{"nctId":"NCT03490994","phase":"PHASE4","title":"Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-04-10","conditions":"Acute Heart Failure","enrollment":150},{"nctId":"NCT03673605","phase":"PHASE4","title":"Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin","status":"WITHDRAWN","sponsor":"PharmEvo Pvt Ltd","startDate":"2016-12-30","conditions":"Mitral Valve Stenosis, Atrial Fibrillation","enrollment":""},{"nctId":"NCT02100228","phase":"PHASE4","title":"Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07-14","conditions":"Atrial Fibrillation","enrollment":1500},{"nctId":"NCT03462446","phase":"","title":"Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-01","conditions":"Atrial Fibrillation","enrollment":249},{"nctId":"NCT02522221","phase":"PHASE3","title":"Tecarfarin Anti-Coagulation Trial (TACT)","status":"UNKNOWN","sponsor":"Espero Biopharma","startDate":"2018-06-01","conditions":"Thromboembolism, Thrombosis","enrollment":1000},{"nctId":"NCT02227550","phase":"PHASE4","title":"Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy","status":"COMPLETED","sponsor":"Atrial Fibrillation Network","startDate":"2014-12","conditions":"Atrial Fibrillation","enrollment":676},{"nctId":"NCT02987062","phase":"","title":"MultiCenter expeRience in AFib Patients Treated With OAC (CRAFT)","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2016-11","conditions":"Atrial Fibrillation","enrollment":2000},{"nctId":"NCT02823093","phase":"","title":"Aortic Calcification and Vitamin K Antagonists","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2016-04","conditions":"Vascular Calcification","enrollment":338},{"nctId":"NCT02429453","phase":"NA","title":"FFP Versus PCC in Intracranial Hemorrhage","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2015-04","conditions":"Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous","enrollment":""},{"nctId":"NCT00788736","phase":"","title":"Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2008-09","conditions":"Venous Thromboembolism","enrollment":2537},{"nctId":"NCT00928915","phase":"PHASE4","title":"International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2009-07","conditions":"Intracranial Hemorrhages","enrollment":54},{"nctId":"NCT01285661","phase":"PHASE3","title":"Optimal Duration of Anticoagulation in Deep Venous Thrombosis","status":"COMPLETED","sponsor":"University of Padova","startDate":"2010-03","conditions":"Deep Vein Thrombosis of Lower Limb, Lower Extremity Deep Venous Thrombosis Recurrent","enrollment":584},{"nctId":"NCT01036802","phase":"PHASE2","title":"Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-12","conditions":"Pulmonary Hypertension","enrollment":3},{"nctId":"NCT01348074","phase":"PHASE2","title":"Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist","status":"COMPLETED","sponsor":"McMaster University","startDate":"2011-04","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Disease","enrollment":104},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Atrial Fibrillation","enrollment":1504},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":"Venous Thromboembolism, Neoplasms","enrollment":56},{"nctId":"NCT02273609","phase":"","title":"INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA)","status":"COMPLETED","sponsor":"Vivencio Barrios","startDate":"2014-02","conditions":"Atrial Fibrillation and Flutter","enrollment":1524},{"nctId":"NCT00645853","phase":"PHASE2","title":"Long-term Safety in Atrial Fibrillation Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Persistent or Permanent Nonvalvular Atrial Fibrillation","enrollment":523},{"nctId":"NCT00684307","phase":"PHASE2","title":"Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Nonvalvular Atrial Fibrillation","enrollment":1084},{"nctId":"NCT00070655","phase":"PHASE3","title":"Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Atrial Fibrillation","enrollment":4673},{"nctId":"NCT00691470","phase":"PHASE2, PHASE3","title":"Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation","status":"UNKNOWN","sponsor":"ARYx Therapeutics","startDate":"2008-05","conditions":"Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease","enrollment":600},{"nctId":"NCT00966290","phase":"PHASE4","title":"Anticoagulant Clinics and Vitamin K Antagonists","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2003-02","conditions":"Blood Coagulation Disorders","enrollment":1006},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACCIDENTAL OVERDOSE"},{"count":1,"reaction":"INTERNATIONAL NORMALISED RATIO INCREASED"}],"_approvalHistory":[],"publicationCount":113,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vitamin K antagonist(warfarin)","genericName":"Vitamin K antagonist(warfarin)","companyName":"Joon Bum Kim","companyId":"joon-bum-kim","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}